Practice
Featured experience
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Azul $800 million secured notes offering
The senior secured notes are due 2028
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
NBCUniversal partnership with MultiChoice to relaunch Showmax using Peacock
We are advising NBCUniversal on the transaction to relaunch MultiChoice’s Showmax service using the Peacock platform
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares…
Sumo Logic $325.6 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $325.6 million initial public…
Orogen Group acquisition of a majority interest in Westcor Land Title Insurance
Davis Polk is advising The Orogen Group on its acquisition of a majority interest in Westcor Land Title Insurance Company…
Spirit Airlines $850 million senior notes offering
Davis Polk advised Spirit Airlines, Inc. in connection with a Rule 144A/Regulation S offering of $850 million aggregate…
Sterling Equities sale of the New York Mets
We advised Sterling Equities on the sale
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
Emerson $1.6 billion acquisition of Open Systems International
Davis Polk is advising Emerson Electric Co. on its $1.6 billion acquisition of Open Systems International, Inc.
Emerson,…
American Well strategic partnership with Google Cloud
Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver…
Bristol Myers Squibb acquisition of Forbius
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and…
CureVac $245.3 million IPO
Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…